Mineralys Therapeutics, Inc. (MLYS) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Radnor, PA, United States. वर्तमान CEO हैं Jon Congleton.
MLYS के पास है IPO तिथि 2023-02-10, 51 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $1.81B.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
